生命科学资讯

#ASH25: AstraZeneca's dual-targeting CAR-T sees similar responses in Western patients as in China

#ASH25: As one door closes for Regeneron’s lymphoma bispecific, another reopens

Apple Tree Partners scores legal win against alleged holdout Russian investor

ACIP vote, more FDA turnover; Introducing Endpoints Signal; ARCH, Parker Institute building next cancer bet; and more

ORIC’s lung cancer pill shows promise in some settings but is dropped for HER2 mutations

Bristol Myers expands Breyanzi approval to marginal zone lymphoma

ACIP drops universal hepatitis B birth dose recommendation

NICE adds further details on how the UK will pay more for drugs

Denali drug hold; Intercept layoffs; Capital raises for Immatics, Capricor and Protara

Rapport shares updated results from Phase 2 study of seizure drug

Biopharma sentiment hit a turning point in October

OTR Therapeutics gets $100M from Pfizer Ventures, others to build asset portfolio

German court stops Merck from selling subcutaneous Keytruda in patent battle with Halozyme

Ex-Intercept CEO takes over at Altimmune; Carolyn Bertozzi leaves Alnylam's board

Praxis stops pivotal trial of rare epilepsy drug early for efficacy

A year of scrutiny for health insurers

ACIP delays vote on hepatitis B birth dose to Friday

Prasad's claim of 10 Covid vaccine deaths may be an overcount: FDA sources

Trump administration pushes end-of-term deadline for ‘most favored nation’ promises

UniQure restates FDA's negative feedback on Huntington's trial; Neurimmune's expanded AstraZeneca alliance